EyePoint Pharmaceuticals (EYPT) Tops Q1 EPS by 2c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q1 EPS of ($0.65), $0.02 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $24.45 million versus the consensus estimate of $7.87 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Phoenix Education Partners, Inc. (PXED) Misses Q3 EPS by 14c; Offers Outlook
• Gladstone Capital Announces Monthly Cash Distributions for July, August and September 2026 and Conference Call Date
• SCHMID Group raises 2026 order intake guidance to €125-€150M